Inclusion Criteria:

- Age >= 1 year old and =< 21 years old;

- Refractory solid tumors, histologically proven at diagnosis (no additional biopsy
needs to be performed for the purpose of the study);

- Relapsed or refractory solid tumors after standard treatment or phase II, III-IV
clinical trials treatment have failed;

- Karnofsky or Lansky status >= 70%;

- Life expectancy >= 8 weeks;

- No chemotherapy / radiotherapy within 4 weeks before entry into the study;

- Adequate biological parameters :

- Absolute neutrophil count >= 1.0 x 109/L;

- Platelet count >= 100 x 109/L;

- Hemoglobin >= 8 mg/dL;

- Total bilirubine =< 1.5 ULN;

- Transaminases =< 2.5 ULN (=< 5 ULN in case of liver metastases);

- Creatinine clearance (Cockroft) >= 70 mL/min/1.73 m2;

- Normal coagulation profile with prothrombin >= 70%, TCA =< 35 and fibrinogen >=
2 g/L;

- Patients with 1 to 3 previous therapeutic lines are eligible;

- No current grade >= 2 organ toxicity based on NCI-CTCAE version 3.0;

- All patients with reproductive potential must have an effective method of birth
control while on study;

- Negative pregnancy test in females when indicated;

- Informed written consent signed by patients or their parents or legal guardians;

- Patient who was informed of the results of prior medical consultation;

- Patient having a social insurance.

Exclusion Criteria:

- Patient with a constitutional anomaly of coagulation and/or of hemostasis (type
hemophilia, von Willebrand disease, congenital clotting factor deficit, platelet
disorder), exposing them to increased risk of bleeding;

- Pre-treatment with a mTOR inhibitor;

- Other simultaneous malignancy;

- Concurrent administration of any other anti-tumour therapy;

- Known hypersensitivity or contraindication to study drugs or ingredients;

- Severe concomitant disease (e.g. infection disease);

- Patient unable for medical follow-up;

- Pregnancy and/or lactation;

- Patient included in another clinical drug trial;

- Patient taking drugs interfering with pharmacology of rapamycin and/or irinotecan
(e.g. drugs interfering with CYP3A4);

- Patient under judicial protection.